Stepwise tapering of biologics in stable RA was non-inferior to continuing full dose

Design

Multicentre, open-label, randomised non-inferiority trial, 24 weeks

Population

348 adults with RA in sustained low disease activity on b/tsDMARDs

Primary outcome

Maintenance of DAS28-ESR low disease activity at week 24

Effect

88.2% tapering vs 89.6% continuation; risk difference −1.43% (95% CI −8.09 to 5.23)

This multicentre, open-label, randomised non-inferiority trial enrolled 348 people with rheumatoid arthritis who had held low disease activity (DAS28-ESR) for at least six months on stable biologic or targeted synthetic DMARDs. They were assigned to continue full dosing or to a structured stepwise taper, and followed for 24 weeks.

Low disease activity was maintained in 88.2% of the tapering group and 89.6% of the continuation group, a difference of about 1.4 percentage points that met the prespecified non-inferiority margin of 10 points. Most patients who worsened regained low disease activity after protocol-guided re-escalation. Some secondary measures favoured continuation, and adverse events were uncommon in both groups.

For a resource-limited system, the attraction is obvious: biologic cost is a major barrier in India, and a structured taper can cut drug use without losing control in most patients.

The trial ran for only 24 weeks, was open-label, and the margin of 10 points is generous. It supports offering a structured taper to stable patients who want it, with close follow-up and a clear plan to step back up, rather than routine tapering for everyone.

• Offer a structured taper to RA patients stable in low disease activity for six months or more who wish to try it.
• Reduce dose in steps with scheduled reviews rather than stopping.
• Restart the previous dose promptly if disease worsens; most patients regained control.
• Monitor DAS28 or SDAI closely during the taper.
• Discuss cost savings openly, as they matter to many patients.

Why it matters

It supports cutting the dose of costly drugs in stable patients without giving up control.

Don't overread it

Open-label, 24 weeks only, with a generous margin; longer-term outcomes and joint damage were not assessed.

The statistics, in plain English

A risk difference of −1.43% with an interval from −8.09% to 5.23% stays inside the −10% non-inferiority margin, so tapering was not meaningfully worse by the trial's definition. A 10-point margin is wide, and 24 weeks is short, so longer-term flare risk is unknown.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.